Article | August 10, 2022

Pursuing Hybrid Funding Models With Silence Therapeutics' Craig Tooman

Source: Cytiva

Growing a biotech company from the ground up takes more than solid science. Without the funding and structure needed to break through a competitive and volatile market, many nascent companies and promising therapeutics can stall out well before reaching their commercial potential.

Craig Tooman, president and CEO of Silence Therapeutics, has spent decades working on securing funding for a range of companies both large and small. Silence has pioneered the design and development of short interfering RNAs (siRNAs), which target and “silence” specific disease-associated genes in cells using the body’s natural process of RNA interference. But for Tooman, it’s the company’s approach to finance that stands to help its pioneering science achieve ultimate success. Tooman recently sat down with The Business of Biotech podcast to explore his own approach to weathering an uncertain market, as well as how Silence is innovating across its business.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma